Esperion Therapeutics Stock Forecast, Price & News

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ESPR stock has decreased by 39.6% and is now trading at $25.93.
View which stocks have been most impacted by COVID-19.

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Esperion Therapeutics stock.
View analyst ratings for Esperion Therapeutics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Esperion Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Esperion Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees.

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Esperion Therapeutics.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($3.07) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($3.52) by $0.45. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to analysts' expectations of $4.04 million. Esperion Therapeutics had a negative trailing twelve-month return on equity of 629.88% and a negative net margin of 46.15%. The company's revenue was up 290.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.52) earnings per share.
View Esperion Therapeutics' earnings history.

12 equities research analysts have issued twelve-month price targets for Esperion Therapeutics' shares. Their forecasts range from $35.00 to $191.00. On average, they expect Esperion Therapeutics' share price to reach $79.08 in the next twelve months. This suggests a possible upside of 205.0% from the stock's current price.
View analysts' price targets for Esperion Therapeutics or view Wall Street analyst' top-rated stocks.

Some companies that are related to Esperion Therapeutics include Axsome Therapeutics (AXSM), Xencor (XNCR), Karuna Therapeutics (KRTX), Intra-Cellular Therapies (ITCI), Deciphera Pharmaceuticals (DCPH), Amarin (AMRN), Arcus Biosciences (RCUS), Zymeworks (ZYME), ADC Therapeutics (ADCT), Ligand Pharmaceuticals (LGND), Stoke Therapeutics (STOK), Seres Therapeutics (MCRB), Praxis Precision Medicines (PRAX), Shattuck Labs (STTK) and Harmony Biosciences (HRMY).
View all of ESPR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include (ALDW) (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), The Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Esperion Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (2.12%) and Pacer Advisors Inc. (0.02%). Company insiders that own Esperion Therapeutics stock include Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends for Esperion Therapeutics.

ESPR stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, and Pacer Advisors Inc.. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech, and Timothy M Mayleben.
View insider buying and selling activity for Esperion Therapeutics or or view top insider-buying stocks.

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ESPR stock can currently be purchased for approximately $25.93.

Esperion Therapeutics has a market capitalization of $722.85 million and generates $148.36 million in revenue each year. The biopharmaceutical company earns $-97,170,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Esperion Therapeutics employs 193 workers across the globe.

The official website for Esperion Therapeutics is www.esperion.com.

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]